Bruce F. Kimler, PhD
Bachelor of Arts, University of Texas at Austin
Master of Arts, University of Texas at Austin
Doctor of Philosophy, University of Texas at Austin
Dr. Kimler completed his Bachelor of Arts (1970), Master of Arts (1971), and Doctorate of Philosophy (1973) degrees at the University of Texas at Austin. Dr. Kimler completed his post-doctoral education in the Division of Biological and Medical Research at Argonne National Laboratory in Argonne, Illinois, and in the Laboratory of Experimental Radiation Oncology in the Department of Radiation Therapy and Nuclear Medicine at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania. Since 1977, Dr. Kimler has devoted his academic career to the Department of Radiation Oncology (formerly Department of Radiation Therapy) at the University of Kansas Medical Center. He was promoted to Associate Professor in 1980 and Full Professor in 1984. During his career he has also held secondary appointments in the Department of Radiation Biophysics at the University of Kansas in Lawrence, Kansas and at the International Molecular Cytology Program of the Instituto de Investigaciones Citologicas de la Caja de Ahorros de Valencia in Valencia, Spain. Dr. Kimler is also a Graduate Faculty Member of the Department of Pharmacology, Toxicology, and Therapeutics.
Dr. Kimler's areas of research interest include:
- Development and utilization of biomarkers for prediction, prevention, and detection of breast cancer; and use in the conduct of Phase I and II clinical trials of potential chemopreventive agents and strategies.
- Use of animal models to investigate the process and prevention of mammary gland cancer, to inform parallel clinical trials with the same interventions.
- Analysis of retrospective clinical data for elucidation of prognostic and predictive factors related to clinical outcomes.
- The development of biological test systems by which the interactions of ionizing radiation and cancer therapeutic modalities can be tested. These studies assess, at the experimental level, the potential use of new combined modality therapies for cancer treatment. Clinical trials are then conducted to evaluate the efficacy of new cancer therapeutic approaches.